Milpitas, Calif.-based Bigfoot Biomedical Inc. has raised $37 million in an initial tranche of a series B round to advance its development and clinical testing of a pair of diabetes products. These include an infusion pump-based, closed-loop, automated insulin delivery system, known as Bigfoot Loop, and an auto-titrating, connected, insulin pen-based system, known as Bigfoot Inject. Read More
